Rockville, MD – The ARVO Foundation for Eye Research (AFER) and Pfizer Ophthalmics are pleased to announce a series of awards named in honor of Carl B. Camras, MD. Up to three awards of $10,000 each will be presented annually for a period of 10 years to early career researchers.
The AFER/Pfizer Ophthalmics/Carl Camras Translational Research Awards celebrate the life and achievements of Dr. Camras, who passed away earlier this year. Dr Camras was a glaucoma specialist and research scientist who was most widely recognized for developing prostaglandin analogues for the treatment of elevated IOP in patients with glaucoma. During his distinguished career, he took a personal interest in developing the next generation of eye and vision researchers.
"Like Carl Camras, Pfizer Ophthalmics is dedicated to making a difference in the lives of patients by collaborating with stakeholders to advance the science and care in the field of eye disorders," said Robert Besthof, Global Commercial Leader for Pfizer Ophthalmics.
Award recipients will be selected based on their excellence in research and their fundamental scientific discoveries, concepts and novel technologies that have led to or have the promise of leading to the prevention, treatment and diagnosis of eye disease.
Pfizer Ophthalmics is supporting the awards through a donation to AFER. Up to the three annual awards will be presented for the next 10 years at the ARVO Annual Meeting beginning in May 2010.
"AFER is proud to have the opportunity to honor early career researchers for their achievements through the AFER/Pfizer Ophthalmics Translational Research Awards," added Gary Abrams, MD, Chairman of AFER's Board of Governors. "We are grateful for Pfizer Ophthalmics' support and commitment to life-changing ophthalmic research."
2010 AFER/Pfizer Ophthalmic/Carl Camras Research Awards
AFER is currently accepting nominations online for the 2010 Awards. The deadline for nominations is February 1, 2010. Recipients will be notified in early April, and the awards will be presented on Sunday, May 2, 2010 at the Keynote Session of the 2010 ARVO Annual Meeting in Fort Lauderdale, Fla. Please visit www.arvofoundation.org/pfizercamrasawards.
Members of the Association for Research in Vision and Ophthalmology are a community of more than 12,600 vision and ophthalmology researchers from over 80 countries. ARVO is the largest eye and vision research organization in the world. We aim to help cure and prevent blindness through research, training, publication and knowledge-sharing in vision and ophthalmology. For more information, visit www.arvo.org.
The ARVO Foundation for Eye Research complements ARVO's mission to cure and prevent blindness and eye disease by providing funds for innovative and novel vision research. The Foundation also supports training for eye researchers around the world; leads initiatives that encourage new vision scientists from emerging countries; and fosters global research collaboration. Learn more at www.arvofoundation.org.
Pfizer Ophthalmics, a division of Pfizer Inc, is committed to preserving sight and eliminating preventable blindness. Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them. Its current product line includes the most prescribed treatment to lower elevated eye pressure in patients with ocular hypertension (abnormally high eye pressure) or open-angle glaucoma. Pfizer Ophthalmics also markets a treatment for neovascular age related macular degeneration outside the US.